B.R.A.I.N. Biotechnology Research and Information Network AG

B. R. A. I.

N. Biotech develops innovative biosolutions through contract research and development, focusing on enzyme technology, microbial strain development, and bioprocess optimization for diverse industrial applications. Founded in 1993 and headquartered in Zwingenberg, Germany, B. R.

A. I. N. Biotech specializes in biosolutions for industrial applications.

The company has executed two deals, with its most recent deal being an IPO in February 2016, raising EUR 48. 3 million. The CEO is Aryan Moelker. B.

R. A. I. N.

Biotech specializes in providing innovative biosolutions tailored for industrial applications, primarily focusing on contract research and development services in enzyme technology, microbial strain development, and bioprocess development. Their core offerings include the engineering of enzymes designed for specific industrial processes, the development of microbial strains optimized for production efficiency, and the enhancement of bioprocesses to scale up production capabilities. These solutions are utilized by a diverse clientele, including companies in the life sciences, food and beverage, and environmental sectors, aiming to improve product quality, optimize manufacturing processes, and increase sustainability. B.

R. A. I. N.

Biotech serves clients across various geographical markets, including Europe, North America, and parts of Asia, positioning itself as a key player in the global biotechnology landscape. B. R. A.

I. N. Biotech's revenue for the most recent year, 2024, was EUR 59,263,546. 30, with an EBITDA of EUR -4,370,647.

20. The company's revenue model is predominantly structured around B2B transactions, where they engage in partnerships with industrial clients requiring specialized research and development services, often resulting in milestone payments linked to project progress. B. R.

A. I. N. Biotech is focusing on launching new products and expanding its market presence.

The company plans to enhance its enzyme and microbial strain development services. The recent IPO in February 2016 for EUR 48. 3 million will support these initiatives, facilitating entry into new regions and enhancing its service capabilities. Specific target markets include Asia and North America, aiming for growth by the end of 2025.